UBE3A

Chr 15AD

ubiquitin protein ligase E3A

Also known as: ANCR, AS, E6-AP, EPVE6AP, HPVE6A, PIX1

This gene encodes an E3 ubiquitin-protein ligase, part of the ubiquitin protein degradation system. This imprinted gene is maternally expressed in brain and biallelically expressed in other tissues. Maternally inherited deletion of this gene causes Angelman Syndrome, characterized by severe motor and intellectual retardation, ataxia, hypotonia, epilepsy, absence of speech, and characteristic facies. The protein also interacts with the E6 protein of human papillomavirus types 16 and 18, resulting in ubiquitination and proteolysis of tumor protein p53. Alternative splicing of this gene results in three transcript variants encoding three isoforms with different N-termini. Additional transcript variants have been described, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

GeneReviewsOMIMResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

Angelman syndromeMIM #105830
AD

Clinical highlights

Gene-disease validity (ClinGen)
Angelman syndrome · ADDefinitivesufficient evidence for diagnostic panels
Interpreting a novel variant
Loss of function is the curated mechanism (Gene2Phenotype) and the gene is intolerant of it in the population — truncating, frameshift and canonical splice variants carry more prior weight here than missense.Curated gene-level mechanism — a prior for triage, not a per-variant call.
3
Active trials
129
Pubs (1 yr)
P/LP submissions
P/LP missense
0.21
LOEUF· LoF intol.
LOF
Mechanism· G2P
📖
GeneReview available — UBE3A
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
  • GTX-102
    ASOPhase 1/2

    Suppresses UBE3A-AS to reactivate the silenced paternal UBE3A.

    Delivery: Intrathecal
  • ION582
    ASOPhase 1/2

    Reactivates paternal UBE3A (same de-repression mechanism).

    Delivery: Intrathecal

Therapeutic landscape as of 2026-07. Educational only. Investigational ≠ available; not medical advice or eligibility. Approved entries are precise; investigational program names/phases are conservative and move fast. Curated from FDA/EMA approvals and the clinical-trial literature; verify against current labeling + ClinicalTrials.gov.

ClinicalTrials.gov

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.21LOEUF
pLI 1.000
Z-score 5.23
OE 0.08 (0.040.21)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
4.40Z-score
OE missense 0.42 (0.370.47)
191 obs / 455.4 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?
LoF OE?0.08 (0.040.21)
00.351.4
Missense OE?0.42 (0.370.47)
00.61.4
Synonymous OE?0.95
01.21.6
LoF obs/exp: 3 / 37.6Missense obs/exp: 191 / 455.4Syn Z: 0.51

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

UBE3A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

VCEP specificationsRett/Angelman-like DisordersReleased
Specifications ↗Panel ↗